BioMarin Pharmaceutical (BMRN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $1.20
- Estimate
- $0.95
- Surprise
- +26.6%
- Revenue (period 2026-06-30)
- $989.7M
- Score at report (before → after)
- 5.4 → 5.6/10
Revenue source: xbrl.
How the report landed
BioMarin Pharmaceutical (BMRN) beat the $0.95 estimate with adjusted EPS of $1.20 — a large 26.6% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.4/10) to Hold at 5.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BMRN Sell at 5.4/10.
1 of the last 4 quarters beat the estimate; this quarter's +26.6% surprise compares with a -18.1% four-quarter average. Next scheduled report: 2026-10-26.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Analyst upside: 34%
What argues against it
- Concentration risk — Customer: Sanofi
- Concentration risk — Supplier: sole source raw material suppliers
- Consecutive earnings misses (3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $61.35
- Price target
- $82.45
- Stop
- $59.29
- Upside to target
- +34.4%
- Reward-to-risk
- 6.5:1
The stock trades at 168.1× trailing but 9.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 26 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-25 — shown for context, not personalized investment advice.
BMRN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $12.04B
- P/E (fwd)
- 9.4
- P/E (ttm)
- 168.1
- 52-week range
- $49.26–$70.98
- Off 52-week high
- 13.6%
- RSI (14)
- 26
- Volume vs avg
- 0.85×
- Score today
- 5.4/10